GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

China National Medicines Corp 600511.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

29.05

-0.82%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥52.47bn

FY2016FY2025

Net income

CN¥2.00bn

FY2016FY2025

Free cash flow

CN¥1.94bn

FY2016FY2025

Shareholders' equity

CN¥18.54bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥52.47bnCN¥50.60bnCN¥49.70bnCN¥45.50bnCN¥46.47bnCN¥40.38bnCN¥44.64bnCN¥38.74bnCN¥36.28bnCN¥34.61bn
Gross profitCN¥3.46bnCN¥3.59bnCN¥3.99bnCN¥3.82bnCN¥3.62bnCN¥3.14bnCN¥3.91bnCN¥3.42bnCN¥2.83bnCN¥2.45bn
Research and developmentCN¥69.3mCN¥73.7mCN¥71.2mCN¥67.0mCN¥55.8mCN¥51.9mCN¥44.9mCN¥34.4mCN¥21.9mCN¥21.0m
Operating incomeCN¥2.62bnCN¥2.68bnCN¥2.94bnCN¥2.69bnCN¥2.45bnCN¥1.91bnCN¥2.44bnCN¥2.04bnCN¥1.77bnCN¥1.54bn
Net incomeCN¥2.00bnCN¥2.00bnCN¥2.15bnCN¥1.96bnCN¥1.75bnCN¥1.38bnCN¥1.60bnCN¥1.40bnCN¥1.14bnCN¥990.2m
Diluted earnings per share2.652.652.842.602.321.832.101.831.482.07

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥36.69bnCN¥34.93bnCN¥32.45bnCN¥29.61bnCN¥27.48bnCN¥24.90bnCN¥24.19bnCN¥21.51bnCN¥20.17bnCN¥7.40bn
Cash and short-term investmentsCN¥11.48bnCN¥10.89bnCN¥10.93bnCN¥8.90bnCN¥7.32bnCN¥6.22bnCN¥5.70bnCN¥5.10bnCN¥5.46bnCN¥1.68bn
Total liabilitiesCN¥16.38bnCN¥15.95bnCN¥14.92bnCN¥13.75bnCN¥13.12bnCN¥11.81bnCN¥12.03bnCN¥10.90bnCN¥10.71bnCN¥3.38bn
DebtCN¥4.58bnCN¥745.7mCN¥473.4mCN¥515.1mCN¥713.3mCN¥802.0mCN¥557.7mCN¥1.03bnCN¥1.24bnCN¥2.36bn
Shareholders' equityCN¥18.54bnCN¥17.13bnCN¥15.78bnCN¥14.21bnCN¥12.78bnCN¥11.44bnCN¥10.54bnCN¥9.23bnCN¥8.18bnCN¥3.52bn
Shares outstanding755m755m755m755m755m754m764m767m770m479m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥2.01bnCN¥1.66bnCN¥2.73bnCN¥2.40bnCN¥1.96bnCN¥1.30bnCN¥1.78bnCN¥981.7mCN¥1.07bnCN¥591.3m
Capital spending−CN¥68.2m−CN¥130.8m−CN¥145.1m−CN¥129.8m−CN¥95.1m−CN¥69.1m−CN¥85.7m−CN¥132.5m−CN¥73.2m−CN¥39.9m
Free cash flowCN¥1.94bnCN¥1.53bnCN¥2.58bnCN¥2.27bnCN¥1.86bnCN¥1.23bnCN¥1.69bnCN¥849.2mCN¥1.00bnCN¥551.4m
Dividends paid−CN¥625.7m−CN¥682.4m−CN¥590.0m−CN¥528.2m−CN¥415.0m−CN¥481.4m−CN¥305.8m−CN¥516.1m−CN¥259.2m−CN¥62.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥13.17bnCN¥13.56bnCN¥13.09bnCN¥13.75bnCN¥12.92bnCN¥12.71bnCN¥12.57bnCN¥13.27bn
Gross profitCN¥770.9mCN¥826.7mCN¥921.1mCN¥925.4mCN¥762.5mCN¥802.8mCN¥925.4mCN¥919.7m
Operating incomeCN¥445.9mCN¥537.9mCN¥542.1mCN¥562.9mCN¥628.5mCN¥600.7mCN¥688.2mCN¥659.7m
Net incomeCN¥405.5mCN¥474.3mCN¥504.3mCN¥543.7mCN¥489.5mCN¥459.0mCN¥518.9mCN¥480.8m
Diluted earnings per share0.540.630.670.720.650.610.690.64
Cash from operations——CN¥4.05bn−CN¥539.0mCN¥382.0m−CN¥1.89bn—CN¥36.0m
Capital spending−CN¥22.0m−CN¥6.0m−CN¥27.0m−CN¥19.0m−CN¥13.0m−CN¥7.0m−CN¥30.0m−CN¥40.0m
Free cash flow——CN¥4.03bn−CN¥558.0mCN¥369.0m−CN¥1.90bn—−CN¥4.0m
Total assetsCN¥36.04bnCN¥36.18bnCN¥36.69bnCN¥35.13bnCN¥34.80bnCN¥35.10bnCN¥34.93bnCN¥34.34bn
Cash and short-term investments——CN¥11.48bnCN¥7.73bnCN¥8.37bnCN¥8.85bnCN¥10.89bnCN¥8.30bn
Debt——CN¥4.39bnCN¥2.42bnCN¥377.6mCN¥523.6mCN¥485.1mCN¥284.3m
Shareholders' equityCN¥18.81bnCN¥19.05bnCN¥18.54bnCN¥18.04bnCN¥17.47bnCN¥17.59bnCN¥17.13bnCN¥16.61bn

Financial ratios

Data as of 25 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin6.6%7.1%8.0%8.4%7.8%7.8%
Operating margin5.0%5.3%5.9%5.9%5.3%4.7%
Net margin3.8%4.0%4.3%4.3%3.8%3.4%
Return on equity10.8%11.7%13.6%13.8%13.7%12.1%
Return on assets5.4%5.7%6.6%6.6%6.4%5.6%
Free cash flow yield10.7%9.2%14.8%13.0%10.6%7.1%
Revenue growth3.7%1.8%9.2%-2.1%15.1%-9.6%
Earnings growth-0.2%-6.8%9.3%12.0%26.9%-13.8%
Current ratio2.08x2.04x2.04x2.02x1.94x1.97x
Debt to equity0.24x0.03x0.02x0.02x0.03x0.04x
Equity ratio50.6%49.0%48.6%48.0%46.5%45.9%
Interest coverage96.51x55.79x65.66x66.86x44.41x10.75x
R&D as a share of sales0.1%0.1%0.1%0.1%0.1%0.1%
Buybacks as a share of market value0.0%-0.0%0.0%0.0%-0.0%1.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.9%5.4%15.8%
Operating income-0.9%6.5%15.3%
Net income0.5%7.6%14.6%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin6.8%7.5%7.6%7.8%
Operating margin5.1%5.5%5.4%5.3%
Net margin3.9%4.1%3.9%3.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings10.912.910.110.713.626.913.012.718.714.6
Price to sales0.40.50.40.50.50.90.50.50.60.4

Dividends and splits

Per share, in the currency the company pays

Paid for 23 years. Last went ex-dividend on 18 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.800.800.8540.7820.700.550.6380.40
  • 2-for-1 split · 3 Jun 2009
  • 9-for-5 split · 25 Jun 2008
  • 1-to-1 reverse split · 23 Aug 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.